Connect your AI

UroGen Pharma URGN Prepaid & Other Current

Prepaid & Other Current at other companies

Johnson & JohnsonJNJ

$4.82B+17.8%

Tyra Biosciences, Inc.TYRA

$11.15M+98.2%

CG OncologyCGON

$23.13M+86.4%

ImmunomeIMNM

$11.62M+100%

LQD

Liquidia CorporationLQDA

$7.61M+56.8%

Krystal Biotech, Inc.KRYS

$16.03M-4.3%

Other financials

Income statement

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is UroGen Pharma's prepaid & other current?: UroGen Pharma (URGN) reported prepaid & other current of $19.53M in Q1 2026.
How has UroGen Pharma's prepaid & other current changed year-over-year?: UroGen Pharma's prepaid & other current increased by 50.4% year-over-year, from $12.98M to $19.53M.
What is the long-term trend for UroGen Pharma's prepaid & other current?: Over 5 years (2020 to 2025), UroGen Pharma's prepaid & other current has grown at a 34.3% compound annual growth rate (CAGR), from $3.36M to $14.67M.
What does prepaid & other current mean?: Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.